PSMA2 and neoplasm: The results showed that PSMA2-overexpressing KOSC3 cells exhibited a reduction in metformin IC50, from 3.92 to 2.05 mM, compared to control cells, and the treatment significantly suppressed PSMA2-induced tumor growth (Fig. 6A).